Among patients with positive AFP before initiation of systemic therapy but negative AFP before surgery (i.e., AFP response = 1), the probability of achieving a pCR for those with MRR (i.e., a reduction of tumor size ≥ 80%) is ≥ 94.5%, which was validated as shown in Table 3. The gene discussed is AFP; the disease is neoplasm.